FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Adiponectin: a therapeutic target in the antiphospholipid syndrome?

Authorized Users Only
2019
Authors
Becarević, Mirjana
Nikolić, B.S
Ignjatović, Svetlana
Article (Published version)
Metadata
Show full item record
Abstract
The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonis...ts, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS.

Keywords:
Adiponectin / Antiphospholipid antibodies / Antiphospholipid syndrome / Inflammation / PPAR-gamma agonist
Source:
Rheumatology International, 2019
Publisher:
  • Springer Verlag
Funding / projects:
  • Biomarkers of organ damage and dysfunction (RS-175036)

DOI: 10.1007/s00296-019-04349-x

ISSN: 0172-8172

WoS: 000478892000004

Scopus: 2-s2.0-85067645374
[ Google Scholar ]
3
2
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3287
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Becarević, Mirjana
AU  - Nikolić, B.S
AU  - Ignjatović, Svetlana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3287
AB  - The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonists, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS.
PB  - Springer Verlag
T2  - Rheumatology International
T1  - Adiponectin: a therapeutic target in the antiphospholipid syndrome?
DO  - 10.1007/s00296-019-04349-x
ER  - 
@article{
author = "Becarević, Mirjana and Nikolić, B.S and Ignjatović, Svetlana",
year = "2019",
abstract = "The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonists, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS.",
publisher = "Springer Verlag",
journal = "Rheumatology International",
title = "Adiponectin: a therapeutic target in the antiphospholipid syndrome?",
doi = "10.1007/s00296-019-04349-x"
}
Becarević, M., Nikolić, B.S,& Ignjatović, S.. (2019). Adiponectin: a therapeutic target in the antiphospholipid syndrome?. in Rheumatology International
Springer Verlag..
https://doi.org/10.1007/s00296-019-04349-x
Becarević M, Nikolić B, Ignjatović S. Adiponectin: a therapeutic target in the antiphospholipid syndrome?. in Rheumatology International. 2019;.
doi:10.1007/s00296-019-04349-x .
Becarević, Mirjana, Nikolić, B.S, Ignjatović, Svetlana, "Adiponectin: a therapeutic target in the antiphospholipid syndrome?" in Rheumatology International (2019),
https://doi.org/10.1007/s00296-019-04349-x . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB